

Q2 Total Revenue

\$109.4M

Furoscix® Q2 Sales

\$22.2M

Afrezza® Q2 Sales

\$17.0M

Tyvaso DPI® Royalties

\$32.4M

Three Major Catalysts Achieved in Q2 2026



Afrezza Pediatrics

- The first alternative to mealtime injections in 100+ years of pediatric treatments
- Unique value proposition addressing patient unmet needs
- Compounds growth as adolescents age into adults

APPROVED



Furoscix ReadyFlow™

- Treats fluid overload in adults with HF or CKD outside the hospital setting
- Reduces administration from hours to seconds
- Supports broader adoption
- Will significantly reduce cost of goods
- Available by end of August 2026

APPROVED



Nintedanib DPI

- Urgent need for new, effective therapies in IPF
- A tolerability profile built for chronic use
- Positive Phase 1b data, validating continued Phase 2 advancement:
 - 0 safety signals
 - 0 bronchospasms
 - 0 discontinuations

PHASE 1b
READOUT Q3

Q2 2026: Beyond the Catalysts

- Afrezza **pediatric launch off to a strong start** — all top 20 key institutions prescribing
- **Breakthrough T1D grant** awarded to advance INHALE-1ST trial
- **Furoscix: strong revenue growth (+43%)** over Q1
- Enrollment underway in the **nintedanib DPI global Phase 2 INFLO-2 study**
- **Ralinepag DPI on track for IND filing by year-end; \$5M milestone payment received** from United Therapeutics

NASDAQ
MNKD

To learn
more, visit us at:
investors.mannkindcorp.com

MNKD Investor Relations:
IR@mnkd.com